LOGIN
Aprotinin reduces blood transfusion in patients undergoing total hip arthroplasty
August 2013
Aprotinin reduces blood transfusion in patients undergoing total hip arthroplasty
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A
Randomized Study of Aprotinin Effect on Transfusions and Blood Loss in Primary THA
Clin Orthop Relat Res. 2007 Dec;465:189-95Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
393 patients undergoing elective primary total hip arthroplasty (THA) were randomized to receive aprotinin (a blood-conserving drug) or a placebo. The primary outcomes were the requirement for transfusions and blood loss. Results from this study indicated the use of aprotinin significantly reduces the requirement for blood transfusions when compared to a placebo treatment. No significant differenc...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.